Skip to content

Pharmacy

Bartell Drugs kicks off flu vaccine program

Bartell Drugs kicks off flu vaccine program

Bartell Drugs has launched a seasonal flu shot program that offers vaccinations at all of its 64 stores as well as via an off-site flu clinic program serving area businesses and retirement communities.

Mylan takes hostile bid to Perrigo stockholders

Mylan takes hostile bid to Perrigo stockholders

As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

NACDS, PhRMA help weigh impact of Rx use on Medicaid costs

NACDS, PhRMA help weigh impact of Rx use on Medicaid costs

The National Association of Chain Drug Stores and the Pharmaceutical Research and Manufacturers of America (PhRMA) co-authored a Health Affairs article on research finding that when prescription drugs are taken as directed by a physician, other medical costs are reduced for certain Medicaid benefici

Mylan to make acquisition bid to Perrigo shareholders

Mylan to make acquisition bid to Perrigo shareholders

Next week, Mylan N.V. plans to make a formal offer directly to the shareholders of Perrigo plc to buy the company. Mylan said Tuesday that it aims to make the bid on Monday, Sept. 14. Under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical has released testosterone gel 1%, a generic version of AndroGel 1% from AbbVie. Par said Wednesday that its testosterone gel 1% product is available in 2.5g and 5g aluminum foil packets containing 25 mg or 50 mg of testosterone, respectively.

Lannett to buy Kremers Urban for $1.23 billion

Lannett to buy Kremers Urban for $1.23 billion

Lannett Co. plans to acquire Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic drug subsidiary of UCB S.A., in a $1.23 billion deal. Lannett said late Wednesday that the acquisition will add a diversified commercial product portfolio of 18 products.